Els Janssens

Medicine · Health Sciences

8h-index539citations55works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(24), Protease and Inhibitor Mechanisms(12), Cancer, Hypoxia, and Metabolism(4), Blood Coagulation and Thrombosis Mechanisms(3), MicroRNA in disease regulation(2)

Publications55 total

Supplemental Data from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 5 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Data from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 12 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 10 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 5 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 9 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 10 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Data from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 9 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 13 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 12 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
Supplemental Data 13 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
2023Open Access
LED Lighting Across Borders. Exploring the Plea for Darkness and Value-Sensitive Design with Libbrecht’s Comparative Philosophy Model
2019· 5 citedOpen Access
Isolation of high-quality RNA from fluorescent activated cell sorted (FACS) zebrafish cells for RNA sequencing purposes
Ghent University Academic Bibliography (Ghent University)·2018
Scrutinizing PHF6 regulatory networks in T-ALL and normal hematopoiesis using zebrafish
Ghent University Academic Bibliography (Ghent University)·2018
Abstract 5815: The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex
Cancer Research·2017
Abstract 4886: The BRIP1 DNA helicase is a 17q dosage sensitive cooperative driver in neuroblastoma
Cancer Research·2017
HBP1 is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex
Ghent University Academic Bibliography (Ghent University)·2017
page 1 of 3Next →

Frequent Co-authors

Frank Speleman(26), Irina Lambertz(21), Shana Claeys(21), Geneviève Laureys(21), Johannes H. Schulte(21), Katleen De Preter(21), Tom Van Maerken(19), Candy Kumps(18), Jan Cools(18), Nadine Van Roy(17), Anneleen Beckers(16), Sara De Brouwer(16), Lieve Moons(15), Marilena De Mariano(15), Jay Gibbons(15), Michaël Porcu(15), Alan Van Goethem(15), Piotr Zabrocki(15), Jorge Vialard(15), Sven Lindner(14)